Table 4 Association between genotypes of NME1 EcoR1 (rs34214448) polymorphism and tumor criteria in the breast cancer group
Genotype | Tumor criteria | OR (95%CI) | P value | |
|---|---|---|---|---|
Tumor stage | ||||
Early (I and II) (n = 23) | Late (III and IV) (n = 38) | |||
G/G | 8 (34.8%) | 15 (39.5%) | R | |
G/T | 9 (39.1%) | 22 (57.9%) | 1.304 (0.410–4.145) | 0.653 |
T/T | 6 (26.1%) | 1 (2.6%) | 0.089 (0.009–0.873) | 0.038 |
LNs’ involvement | ||||
No (n = 19) | Yes (n = 42) | |||
G/G | 8 (42.1%) | 15 (35.7%) | R | |
G/T | 8 (42.1%) | 23 (54.8%) | 1.533 (0.473–4.971) | 0.476 |
T/T | 3 (15.8%) | 4 (9.5%) | 0.711 (0.127–3.993) | 0.699 |
Distant metastasis | ||||
No (n = 46) | Yes (n = 15) | |||
G/G | 13 (28.3%) | 10 (66.7%) | R | |
G/T | 26 (56.5%) | 5 (33.3%) | 0.25 (0.071–0.884) | 0.031 |
T/T | 7 (15.2%) | 0 (0%) | 0 | 0.999 |
ER receptor status | ||||
Positive (n = 44) | Negative (n = 17) | |||
G/G | 18 (40.9%) | 5 (29.4%) | R | |
G/T | 21 (47.7%) | 10 (58.8%) | 1.714 (0.494–5.951) | 0.396 |
T/T | 5 (11.4%) | 2 (11.8%) | 1.44 (0.212–9.782) | 0.709 |
PR receptor status | ||||
Positive (n = 42) | Negative (n = 19) | |||
G/G | 17 (40.5%) | 6 (31.6%) | R | |
G/T | 20 (47.6%) | 11 (57.9%) | 1.558 (0.476–5.104) | 0.464 |
T/T | 5 (11.9%) | 2 (10.5%) | 1.133 (0.172–7.469) | 0.896 |
HER2 receptor status | ||||
Positive (n = 28) | Negative (n = 33) | |||
G/G | 14 (50%) | 9 (27.3%) | R | |
G/T | 11 (39.3%) | 20 (60.6%) | 2.828 (0.928–8.622) | 0.068 |
T/T | 3 (10.7%) | 4 (12.1%) | 2.074 (0.373–11.528) | 0.405 |
Ki-67 level | ||||
High (n = 54) | Low (n = 7) | |||
G/G | 21 (38.9%) | 2 (28.6%) | R | |
G/T | 26 (48.1%) | 5 (71.4%) | 2.019 (0.355–11.478) | 0.428 |
T/T | 7 (13%) | 0 (0%) | 0 | 0.999 |